Dear Editor,

SARS-CoV-2 causes a spectrum of illness, ranging from an asymptomatic state to life-threatening multi-organ failure, and imposes a high socioeconomic burden on its sufferers and on society (Chen *et al.* [@CR3]; Pan *et al.* [@CR9]). Asymptomatic SARS-CoV-2 infection, confirmed by assay with quantitative real-time reverse transcription PCR (qRT-PCR), presented neither clinical symptom nor radiographic abnormality (Pan *et al.* [@CR9]). While T cell responses are crucial for viral control, viral infection also induces significant count decrease and function impairment of T cells (Chen *et al.* [@CR3]; Qin *et al.* [@CR10]). Despite high rate of SARS-CoV-2 asymptomatic infections (Black *et al.* [@CR1]), T cell responses of this population are still largely unknown. Here, we reported the kinetics of CD4^+^ and CD8^+^ T cell responses in an asymptomatic SARS-CoV-2 infected case.

A man in 30s of Hubei resident, who had traveled to Thailand from Wuhan around mid-January, 2020, was tested positive for SARS-CoV-2 upon return to Wuhan on late March and transferred to Wuhan Jinyintan Hospital for isolation. SARS-CoV-2 nucleotide was detected again at days 1--2 in sputum and/or nasopharyngeal swab samples but was undetectable since d5 (Fig. [1](#Fig1){ref-type="fig"}A and Supplementary Table S1). SARS-CoV-2-binding IgM was presented in plasma since d7, while IgG remained undetectable at all detected time points (Fig. [1](#Fig1){ref-type="fig"}A). These results implied that the man was still at the early stage of virus infection at the time of admission. At day 14 post hospitalization, the man was discharged to a designated hotel for another 14-day-isolation. Within the 28-day follow-up, the man presented neither clinical symptom nor CT abnormality (Supplementary Fig. S1, Supplementary Video S1). Taken together, this man was an asymptomatic SARS-CoV-2 infected individual.Fig. 1T cell responses in PBMCs of the asymptomatic patient during SARS-CoV-2 infection. **A** Timeline of the study. SARS-CoV-2 infection was detected by qRT-PCR in nasopharyngeal swab, sputum, and by RBD-specific plasma IgM, IgG using colloidal gold strips. Peripheral blood was collected at the indicated time point post hospitalization for T cell response analysis. **B**--**H** T cell responses in PBMCs of the asymptomatic patient and healthy donors (HD, n = 11). **B**--**E** differentiation, proliferation and activation of T cells. **B** Frequencies of effector T cells (Teff) in CD4^+^ or CD8^+^ T cells. Gating strategies of the naïve (Tna, CD45RO^−^CD27^+^), central memory (Tcm, CD45RO^+^CD27^+^), effector memory (Tem, CD45RO^+^CD27^−^) and effector (Teff, CD45RO^−^CD27^−^) subsets were shown as left panels. **C**--**E** Frequencies of Ki-67^+^ (**C**), PD-1^+^ (**D**) or HLA-DR^+^ (**E**) cells in CD4^+^ or CD8^+^ T cells of the patient and in that of HD. **F** After *ex vivo* stimulation by PMA/Ionomycin for 4.5 h in the presence of BFA and monensin, the production of IFN-γ and IL-17 by CD4^+^ or CD8^+^ T cells were analyzed by intracellular cytokine staining and flow cytometry. **G**--**H** Frequencies of Treg and Treg subsets. **G** Gating strategy and the frequency of CD25^+^CD127^−^ Tregs in CD3^+^CD8^−^CD4^+^ T cells. **H** Gating strategies for Treg subsets and the frequencies of resting Treg cells (rTregs, CD45RA^+^Foxp3^lo^) and activated Treg cells (aTregs, CD45RA^−^Foxp3^hi^) in Tregs.

During the follow-up period, T cell responses of this case were assayed by flow cytometry analysis of the fresh peripheral blood nonnuclear cells (PBMCs). Cell counts of total lymphocytes, CD4^+^ T cells, CD8^+^ T cells as well as the ratio of CD4^+^/CD8^+^ T cells maintained at normal level (Supplementary Fig. S2). Further analysis on the differentiation of CD4^+^ and CD8^+^ T cells showed a significant and gradual increase of effector T cells (CD45RO^−^CD27^−^, Teff) in both CD4^+^ and CD8^+^ T cells (Fig. [1](#Fig1){ref-type="fig"}B). The frequencies of naïve T cells (CD45RO^−^CD27^+^, Tna), central memory T cells (CD45RO^+^CD27^+^, Tcm) in either CD4^+^ or CD8^+^ T cells were not significantly changed, while the effector memory subset (CD45RO^+^CD27^−^, Tem) were slightly increased (Supplementary Figs. S3A, S4A). In consistent with the kinetics of T cell differentiation, proliferation of T cells (assessed by the frequency of transcription factor Ki-67^+^), was much higher than that of healthy donors (HD) at d7 in both CD4^+^ and CD8^+^ T cells. The higher frequency of Ki-67^+^ cells lasted until d22 in CD4^+^ T cells, while rapidly decreased to baseline at d13 in CD8^+^ T cells (Fig. [1](#Fig1){ref-type="fig"}C). The activation of CD4^+^ and CD8^+^ T cells, determined as the percentage of PD-1^+^, HLA-DR^+^ or CD38^+^HLA-DR^+^, were lower than the low limit of HD at d7, peaked at d13, and gradually decreased to a low level that was comparable as the beginning (Fig. [1](#Fig1){ref-type="fig"}D, 1E, Supplementary Fig. S5). The activation and proliferation of each differentiated subsets (Teff, Tna, Tcm, Tem) of CD4^+^ or CD8^+^ T cells all showed the similar trend as the parent populations (Fig. [1](#Fig1){ref-type="fig"}C--[1](#Fig1){ref-type="fig"}E, Supplementary Figs. S3, S4).

Then we examined the function potential of CD4^+^ and CD8^+^ T cells by stimulating PBMCs with polyclonal stimulator PMA and Ionomycin as previously described (Knudson *et al.* [@CR5]; Chang *et al.* [@CR2]; Mazzoni *et al.* [@CR7]; Zheng *et al.* [@CR13]). Notably lower frequencies of IFN-γ producing CD4^+^ (Th1) and CD8^+^ T cells (Tc1) were detected at d7, compared to those of HD. Although the frequencies of Th1 and Tc1 cells gradually increased from d7 to d28, Tc1 was still lower than that of HD at d28 (Fig. [1](#Fig1){ref-type="fig"}F). While kept in the normal range, IL-4 producing CD4^+^ T cells (Th2) gradually increased from d7 to d22 then dropped to the baseline at d28 (Supplementary Fig. S6C). In contrast, frequency of IL-17 producing CD4^+^ T cells (Th17) maintained at remarkably lower level than that in HD, without significant increase in all the tested time points. The IL-4 or IL-17 producing CD8^+^ cells were very rare, and with no significant changes (Supplementary Fig. S6D, Fig. [1](#Fig1){ref-type="fig"}F).

According to the expression of FoxP3 and CD45RA, regulatory T cells (Tregs, CD3^+^CD8^−^CD4^+^CD127^−^CD25^+^) are classified into two suppressive subsets: a slight inhibitory CD45RA^+^FoxP3^lo^ resting Treg cells (rTregs) and a stronger inhibitory CD45RA^−^FoxP3^hi^ activated Treg cells (aTregs) (Miyara *et al.* [@CR8]). The frequency of Tregs gradually increased since d7, peaked at a much higher level than that of HD at d22, then slightly decreased at d28 (Fig. [1](#Fig1){ref-type="fig"}G). The composition of aTregs was much higher than that in HD at d7, then gradually decreased to normal range at d22, though the rTregs maintained at a sustained level as HD (Fig. [1](#Fig1){ref-type="fig"}H). CTLA4 is one of the most important co-inhibitory molecules expressed by Tregs. As shown in Supplementary Fig. S7, The dynamics of CTLA4^+^ in total Tregs and the two subsets were similar, in which the CTLA4^+^ population peaked at d13 and then dropped but without significant changes compared with HD.

Collectively, our study provides novel contributions to understanding the kinetics of T cell responses in an asymptomatic infection case. Although T cells counts were normal, the activation, frequency and function of T cell subsets were aberrant in this case. Specifically, suppressed activation of T cells, reduction of Th1 cells and elevation of aTregs were observed at early stage. Moreover, lower frequencies of Th17 and Tc1 cells were detained even at d28, when the SARS-CoV-2 virus had already become undetectable over 3 weeks. Our data suggested that the function potential of T cells especially Th17 and Tc1 was suppressed in the asymptomatic patient. Nevertheless, there is possibility that the active status of T cells by acute viral infection itself might make the T cells hypo-responsive to the polyclonal stimulator, PMA/ionomycin. If this is the case, the changing tendencies of different functional molecules such as IFN-γ and IL-17 should be much more similar. However, in our study, the longitudinal curve of different functional molecules showed differential responses, which suggested limited interference of viral activation would be added on the effects by PMA/ionomycin stimulation. Additionally, previous studies also showed that the activation of T cells does not lead to hypo-response to PMA/ionomycin polyclonal stimulation (Wu *et al.* [@CR12]; Chen *et al.* [@CR4]).

The elevation of aTregs accompanying with the low activation and suppressed function of T cells at early stage of this asymptomatic case, suggested that aTregs might take part in the suppression of the activation and function of T cells. These T cell response characteristics should be confirmed further in larger cohorts of people with asymptomatic SARS-CoV-2 infection.

T cell responses in this asymptomatic case showed some similarity such as Th1 and Tc1 reduction as well as some differences compared to those reported in the symptomatic cases. Different from this asymptomatic case, significant decrease of T lymphocytes, lower levels of Tregs and remarkable activation of the CD4^+^ and CD8^+^ T cells was reported in the symptomatic COVID-19 cases (Chen *et al.* [@CR3]; Liu *et al.* [@CR6]; Mazzoni *et al.* [@CR7]; Qin *et al.* [@CR10]; Thevarajan *et al.* [@CR11]). The previous reports together with ours pointed out the complicated interactions between viral infection, T cell responses and clinical outcomes, which requires more intensive studies to clarify the role of T cell responses in the control and immunopathology of SARS-CoV-2 infection.
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